Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Original Frontiers Methods/Results: GEO/TCGA expression analyses and feature selection identified four oxaliplatin-sensitivity genes; external GEO/GDSC validation and gene-silencing cell experiments tested functional contribution. Evidence supports a preclinical gene/signature finding; not prospective patient-level treatment selection.
Technology: the ML/deep-learning operation used for the specific result.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- the ML/deep-learning operation used for the specific result.
- Limitation / still unknown
- Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1701328/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.